Valuation: Luoxin Pharmaceuticals Group Stock Co., Ltd.

Market Cap 4.31B 647M 582M 535M 485M 905M 61.46B 921M 6.38B 2.55B 32.41B 2.43B 2.38B 102B P/E 2024
-4.2x
P/E 2025 -17.7x
Enterprise Value 4.85B 729M 655M 603M 546M 1.02B 69.22B 1.04B 7.18B 2.87B 36.5B 2.74B 2.68B 115B EV / Sales 2024
1.98x
EV / Sales 2025 2.48x
Free-Float
59.59%
Yield 2024 *
-
Yield 2025 -
10-26 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
08-20 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-20 Luoxin Pharma's Unit Fined 1.9 Million Yuan for Substandard Drug; Shares Up 3% MT
04-22 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
01-30 Luoxin Pharmaceuticals Group Stock Co., Ltd. Elects Zuo Min, Independent Director CI
12-22 Helix Healthcare BV entered into a binding agreement to acquire an additional 20% stake in Luoxin Aurovitas Pharma Co. Ltd from Luoxin Pharmaceuticals Group Stock Co., Ltd. for $5.1 million. CI
25-10-27 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-29 Luoxin Pharmaceuticals Group Stock plans to raise fund via share private placement RE
25-09-28 Luoxin Pharmaceuticals Group Stock Co., Ltd. announced that it expects to receive CNY 842.4 million in funding CI
25-09-09 Luoxin Pharmaceuticals CFO Resigns MT
25-08-27 Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-07-27 Zhongjue Zhongju Zengli No. 1 Private Securities Investment Fund managed by Shanghai Zhongjue Private Fund Management Co., Ltd. completed the acquisition of 5% stake in Luoxin Pharmaceuticals Group Stock Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP), Karamay Deyi Hengjia Equity Investment Limited Partnership Enterprise and Deyi Investment Management Co., Ltd. CI
25-05-28 Luoxin Pharmaceuticals Gets China's Regulatory Approval for Ibuprofen Injection Solution MT
1 day-0.75%
1 week-5.26%
Current month-17.84%
1 month-17.50%
3 months-16.81%
6 months-26.53%
Current year-17.50%
1 week 3.88
Extreme 3.88
4.33
1 month 3.88
Extreme 3.88
4.95
Current year 3.7
Extreme 3.7
5.75
1 year 3.7
Extreme 3.7
5.82
3 years 3.22
Extreme 3.22
6.74
5 years 3.22
Extreme 3.22
11.45
10 years 3.22
Extreme 3.22
18.89
Manager TitleAgeSince
Chief Executive Officer 40 2023-04-22
Director of Finance/CFO 43 2025-09-07
Investor Relations Contact - -
Director TitleAgeSince
Chairman 40 2020-04-22
Director/Board Member 51 2020-04-22
Director/Board Member 38 2020-04-22
Date Insider Type Main position Quantity % Market Cap. Importance
3/26/20 Buy

Director

10,100 0.0041%
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%-5.26%-24.71%-31.84% 651M
+3.19%+8.48%+74.25%+153.03% 1,224B
-0.73%+2.09%+46.41%+87.64% 662B
+1.41%+3.40%+30.98%+112.26% 514B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+1.55%+72.70%+45.42% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+4.19%+59.72%+78.16% 249B
+3.06%+8.58%+44.03%+122.76% 205B
Average +1.57%+1.61%+40.52%+73.47% 417.75B
Weighted average by Cap. +1.19%+3.04%+53.34%+100.40%

Financials

2024 2025
Net sales 2.65B 398M 358M 329M 298M 556M 37.78B 566M 3.92B 1.57B 19.92B 1.49B 1.46B 62.68B 2.27B 342M 307M 282M 256M 477M 32.44B 486M 3.37B 1.35B 17.11B 1.28B 1.25B 53.82B
Net income -965M -145M -130M -120M -109M -203M -13.78B -206M -1.43B -572M -7.26B -545M -533M -22.86B -289M -43.37M -38.97M -35.86M -32.47M -60.61M -4.12B -61.7M -427M -171M -2.17B -163M -159M -6.83B
Net Debt 1.18B 178M 160M 147M 133M 248M 16.87B 253M 1.75B 701M 8.9B 667M 653M 27.99B 544M 81.72M 73.42M 67.56M 61.17M 114M 7.76B 116M 805M 322M 4.09B 307M 300M 12.87B
Projected Income Statement - Annual - Luoxin Pharmaceuticals Group Stock Co., Ltd.
Logo Luoxin Pharmaceuticals Group Stock Co., Ltd.
Luoxin Pharmaceuticals Group Stock Co Ltd is a China-based company primarily engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on therapeutic areas such as digestive, respiratory, and anti tumor treatments. The Company's products mainly include chemical formulations, active pharmaceutical ingredients (APIs), and traditional Chinese medicines. The Company conducts its operations through two segments. The Pharmaceutical Manufacturing segment engages in the research, development, and production of chemical drug formulations and APIs, with major products including digestive medicines, respiratory medicines, and antibiotics. The Company also operates through the Pharmaceutical Distribution segment. The Company mainly operates its businesses in the domestic market.
Employees
2,962
Date Price Change Volume
26-10-30 CN¥3.960 -0.75% 21,998,470
26-10-29 CN¥3.990 -1.72% 14,155,300
26-10-28 CN¥4.060 +1.25% 21,059,860
26-10-27 CN¥4.010 -6.09% 29,524,580
26-10-26 CN¥4.270 -0.93% 14,195,300
  1. Stock Market
  2. Stocks
  3. 002793 Stock